| | 869901-69-9 Basic information More.. |
| Product Name: | MK-2048 | | Synonyms: | Pyrazino[1',2':1,5]pyrrolo[2,3-d]pyridazine-4-carboxamide, 2-[(3-chloro-4-fluorophenyl)methyl]-8-ethyl-1,2,6,7,8,9-hexahydro-10-hydroxy-N,6-dimethyl-1,9-dioxo-, (6S)-;(S)-2-(3-chloro-4-fluorobenzyl)-8-ethyl-10-hydroxy-N,6-diMethyl-1,9-dioxo-1,2,6,7,8,9-hexahydropyrazino[1',2':1,5]pyrrolo[2,3-d]pyridazine-4-carboxaMide;(6S)-2-[(3-Chloro-4-fluorophenyl)methyl]-8-ethyl-1,2,6,7,8,9-hexahydro-10-hydroxy-N,6-dimethyl-1,9-dioxopyrazino[1',2':1,5]pyrrolo[2,3-d]pyridazine-4-carboxamide;CS-1529;MK-2048 USP/EP/BP;MK-2048 MK2048 | | CAS: | 869901-69-9 | | MF: | C21H21ClFN5O4 | | MW: | 461.87 | | EINECS: | | | Mol File: | 869901-69-9.mol |  |
Use
MK-2048 represents a prototype second generation integrase strand transfer inhibitor (INSTI), it was developed with the goal of retaining activity against viruses containing mutations assiciated with
resistance of first-generation INSTIs, raltegravir (R100312). MK-2048 exhibits inhibitory activity towards HIV integrase and towards HIV replication. It is four times more effective in inhibiting HIV
enzyme integrase than the first generation inhibitor, raltegravir.
|
|
869901-69-9
Recommend Suppliers |
|